Tag Archive for: Mindset Pharma
https://psychedelicspotlight.com/wp-content/uploads/2021/12/Psychedelic_Business_Spotlight_December_31_Mindset_Pharma_Core_One_Laboratories_Psychedelic_Spotlight.jpg 962 1920 Greg Gilman https://psychedelicspotlight.com/wp-content/uploads/2023/01/PS_LOGO_PRIMARY_DOT_WHT-1.png Greg Gilman2021-12-31 18:22:552022-06-07 23:17:01Psychedelic Business Spotlight – December 31
This week in psychedelic business news: Mindset Pharma files another patent for compounds with "perfect microdosing drug profile," and Core One Labs is preparing to capitalize on functional mushroom market.
https://psychedelicspotlight.com/wp-content/uploads/2021/10/Mindset_Pharma_Next_Generation_Psychedelic_Drugs_Psychedelic_Spotlight.jpg 875 1310 Greg Gilman https://psychedelicspotlight.com/wp-content/uploads/2023/01/PS_LOGO_PRIMARY_DOT_WHT-1.png Greg Gilman2021-10-08 19:06:572021-10-08 19:19:32How Mindset Pharma Is Making and Defining ‘Next-Generation Psychedelic Drugs’
CEO James Lanthier compares psychedelic medicines to aspirin, and explains why the company's lead candidate may be better than psilocybin.
https://psychedelicspotlight.com/wp-content/uploads/2021/10/Psychedelic_Spotlight_James_Lanthier.jpg 855 1200 Psychedelic Spotlight https://psychedelicspotlight.com/wp-content/uploads/2023/01/PS_LOGO_PRIMARY_DOT_WHT-1.png Psychedelic Spotlight2021-10-06 04:39:422022-06-08 12:54:54Interview with James Lanthier, CEO of Mindset Pharma
In our conversation, James goes into detail about Mindset’s new lead drug candidate MSP-1014, when the company expects to take the drug to clinical trials, and why next generation drugs are an important commercial opportunity for anyone looking to invest in the psychedelic sector.
https://psychedelicspotlight.com/wp-content/uploads/2021/09/Psychedelic_Spotlight_Business_Spotlight_Sept_24.jpg 962 1920 Greg Gilman https://psychedelicspotlight.com/wp-content/uploads/2023/01/PS_LOGO_PRIMARY_DOT_WHT-1.png Greg Gilman2021-09-24 17:08:482022-06-07 23:24:26Psychedelic Business Spotlight: September 24, 2021
This week in psychedelic business news: two patents may revolutionize the medical application of psychedelic compounds; DMT and ibogaine clinical trials show promise; and stock news for psychedelic investors.
https://psychedelicspotlight.com/wp-content/uploads/2021/09/Psychedelic_Business_Spotlight_September-17.jpg 962 1920 Emily Jarvie https://psychedelicspotlight.com/wp-content/uploads/2023/01/PS_LOGO_PRIMARY_DOT_WHT-1.png Emily Jarvie2021-09-17 17:08:242022-06-07 23:24:40Psychedelic Business Spotlight: September 17, 2021
This week in psychedelic business news: Wesana teams up with MAPS, MindBio Therapeutics announces world-class research and drug development facility, and Awakn Life Sciences buys up ketamine clinics across the Nordics.
https://psychedelicspotlight.com/wp-content/uploads/2021/09/Psychedelic_Spotlight_Business_Roundup_Sept_10_Psychedelic_Spotlight.jpg 962 1920 Emily Jarvie https://psychedelicspotlight.com/wp-content/uploads/2023/01/PS_LOGO_PRIMARY_DOT_WHT-1.png Emily Jarvie2021-09-10 15:01:302022-06-07 23:24:46Psychedelic Business Spotlight: September 10, 2021
This week in psychedelic business news: major DMT development for stroke treatment; a propriety psilocybin formulation has potential to treat obesity; two more companies join the OTC Pink Market.
https://psychedelicspotlight.com/wp-content/uploads/2021/09/Psychedelic_Spotlight_Business_Roundup_Sept-3_Take-2.jpg 962 1920 Emily Jarvie https://psychedelicspotlight.com/wp-content/uploads/2023/01/PS_LOGO_PRIMARY_DOT_WHT-1.png Emily Jarvie2021-09-03 17:19:052022-06-07 23:24:54Psychedelic Business Spotlight: September 3, 2021
"Magic Truffle" producer and distributor Red Light Holland has had a very busy week, and Filament Health files a "milestone" patent.
https://psychedelicspotlight.com/wp-content/uploads/2021/08/DMT_Mindset_Pharma_seratonin_Psychedelic_Spotlight.jpg 878 1310 Emily Jarvie https://psychedelicspotlight.com/wp-content/uploads/2023/01/PS_LOGO_PRIMARY_DOT_WHT-1.png Emily Jarvie2021-08-31 17:41:072021-08-31 17:41:11Mindset Pharma’s DMT-Inspired Drug Candidates Could Address Serotonin Syndrome Challenge
“The data suggests that we have a new drug that may be at least as effective, if not more effective, than 5-MeO-DMT and, more importantly, it looks like it is much safer," says Mindset Pharma CEO James Lanthier.
https://psychedelicspotlight.com/wp-content/uploads/2021/08/Business_Roundup_Aug6.jpg 963 1920 Jennifer Walker-Journey https://psychedelicspotlight.com/wp-content/uploads/2023/01/PS_LOGO_PRIMARY_DOT_WHT-1.png Jennifer Walker-Journey2021-08-06 16:57:512021-08-06 18:58:55Psychedelic Business Spotlight: August 6, 2021
Another clinic gets approval to conduct MDMA research, and new psychedelic research facilities open in Australia and the U.S., plus two game-changing psilocybin patents.
https://psychedelicspotlight.com/wp-content/uploads/2021/08/Mindset_Pharma_Patent_Novel_Psilocybin_Synthesis_Psychedelic_Spotlight.jpg 930 1310 Emily Jarvie https://psychedelicspotlight.com/wp-content/uploads/2023/01/PS_LOGO_PRIMARY_DOT_WHT-1.png Emily Jarvie2021-08-03 19:44:072021-08-03 20:29:00Mindset Pharma Files Patent for Quickest, Cheapest Method to Synthesize Psilocybin
"Based on our research, we think we're able to get to psilocybin in fewer steps than any of the other published methods," says the company's CEO.